SELECT TRIAL: Semaglutide reduces cardiovascular events among overweight or obese patients with cardiovascular disease in the absence of diabetes
Key Points: Semaglutide, a glucagon-like peptide-1 (GLP-1) analogue, has previously been shown…
Tag: AHA23